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OIndications for revascularization in patients with left ventricular
dysfunction: Evidence and uncertaintiesRobert O. Bonow, MD, MSSurgical treatment of coronary artery disease (CAD) ranks
among the greatest advances in medicine in the 20th
century and remains the leading form of cardiovascular
surgery in the world’s developed countries, despite
improvements in medical therapy and the growth of
percutaneous coronary intervention (PCI). In 2010, nearly
400,000 coronary artery bypass graft (CABG) procedures
were performed in the United States.1 In-hospital mortality
rates related to the procedure have declined substantially for
both men and women, despite increases in overall age and
comorbidities.2
Among symptomatic patients, revascularization with
either PCI or CABG results in better symptom relief and
improved quality of life compared with medical
management.3,4 CABG provides superior long-term
survival rates compared with PCI in patients with the
most-complex multivessel disease and those with
diabetes.5-8 Thus, for the most part, the role of the
CABG in the management of CAD is well established,
with strong evidence-based guidelines and recommenda-
tions to improve outcomes in patients with left main dis-
ease, 3-vessel disease, and severe stenosis of the
proximal left anterior descending artery.9-12 However,
the impact of having CABG on survival in patients with
left ventricular (LV) dysfunction, particularly severe LV
dysfunction, remains a subject of considerable debate
and uncertainty.
Numerous early studies of CABG versus medical therapy
in patients with LV dysfunction uniformly suggested that
CABG results in improved survival, with enhanced survival
rates compared with medical management, ranging from
10% to 50%.13-17 However, these nonrandomized studies
were predominately retrospective and predate the use
of modern evidence-based medical therapies for LV
dysfunction; many predate the use of internal mammary
grafts.
In addition, the seminal randomized trials of CABG
versus medical therapy fail to provide definitive insights in
the case of such patients, partly because these trials wereFrom the Center for Cardiovascular Innovation, Department of Medicine,
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for LV dysfunction with beta-adrenergic blockers,
angiotensin converting–enzyme inhibitors, and statins. In
addition, patients with a severely reduced LV ejection
fraction (EF) were excluded from randomization. Although
26% of patients in the Veterans Administration Cooperative
Study18 had EF values<45%, none was considered to have
severe LV dysfunction. The European Surgery Study19
excluded patients with an EF<50%. The Coronary Artery
Surgery Study excluded patients with an EF<35% and
those in New York Heart Association functional class
III-IV.20 The Coronary Artery Surgery Study enrolled only
160 patients with mild-moderate LV dysfunction (EF,
35%-49%); the finding of improved survival with surgical
therapy compared with medical therapy in patients who
had 3-vessel disease and this degree of LV dysfunction
was based on a total of only 78 patients.21 The Coronary
Artery Bypass Graft Surgery Trialists Collaboration
meta-analysis of 7 clinical trials of CABG surgery versus
medical therapy3 included only 178 patients (7% of the
total) with an EF<40%.
More recent randomized trials investigating outcomes in
patients receiving intensive contemporary medical therapy
for CAD versus myocardial revascularization4,22,23 have
largely excluded patients with severe LV dysfunction. In
addition, prospective randomized trials of CABG versus
PCI have enrolled predominately patients with normal LV
function, and none focused specifically on patients with a
depressed EF.5,6,24
THE SURGICAL TREATMENT FOR ISCHEMIC
HEART FAILURE TRIAL
The Surgical Treatment for Ischemic Heart Failure
(STICH) trial25 emerges as the first and only prospective
randomized trial designed to determine the impact of
CABG when it is added to evidence-based medical therapy
in patients with CAD and an EF 35%. The STICH trial
investigated 2 hypotheses: that survival is enhanced with
CABG plus evidence-based medical therapy compared
with medical therapy alone in patients with ischemic heart
failure (the revascularization hypothesis); and that CABG
plus surgical ventricular reconstruction (SVR) provides a
survival advantage compared with CABG alone, in patients
with an EF 35% undergoing revascularization who have
dominant LV anterior akinesia or dyskinesia (the SVR
hypothesis). Patients with left main stenosis or significant
angina pectoris (Canadian Heart Association functional
class III-IV) were eligible to participate in the SVRdiovascular Surgery c Volume 148, Number 6 2461
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hypothesis.
Revascularization Versus Medical Therapy
The STICH trial revascularization hypothesis enrolled
1212 patients in 99 international sites, with 602 randomized
to receive medical therapy and 610 to receive CABG plus
medical therapy.26 In patients undergoing surgery, the goal
was to achieve complete revascularization and implement
internal mammary grafts whenever possible; internal
mammary grafts were employed in 91% of patients.
Evidence-based medical therapy in both the surgical
and medical arms of the study achieved high levels of
adherence, including beta-blocking agents (in 91% of
patients at 1 year); angiotensin converting–enzyme
inhibitors or angiotensin-receptor antagonists (91%);
statins (91%); and aspirin (88%), with 93% receiving either
aspirin or warfarin.
The primary outcome was all-cause mortality. The
principal result26 was the lack of significant difference in
all-cause mortality between the 2 groups during the
56-month mean follow-up period, with 41% and 36%
mortality in those assigned to medical therapy and CABG,
respectively (P ¼ .12). Thus, using the prespecified
intention-to-treat analysis, the study must be interpreted as
a negative trial.
However, several considerations suggest a more favor-
able outcome in those receiving CABG. First, secondary
endpoints included cardiovascular mortality and the
combination of all-cause mortality plus cardiovascular
hospitalization, and both of these endpoints were
significantly reduced by CABG compared with medical
therapy (P ¼ .05 and P< .001, respectively). Second, a
small but important number of crossovers occurred, with
55 patients randomized to the CABG arm who never
received CABG, and 65 patients randomized to medical
therapy who underwent an early CABG procedure.
Analysis of outcomes based on patients who actually
received CABG versus medical therapy reveals highly sig-
nificant reductions in mortality with CABG, using either an
analysis of actual treatment received or a per-protocol
analysis that excludes the crossovers (P < .001 and
P ¼ .005, respectively).26,27 Finally, symptom status and
quality of life were substantially better in patients
randomized to receive CABG throughout the duration of
follow-up.28
Thus, depending on the perspective taken—that of a
clinical trialist (intention-to-treat), or that of patients,
clinicians, and surgeons (actual treatment received)—the
STICH study can be interpreted as either a negative or
positive trial, with respect to the impact of CABG on
survival of patients with ischemic LV dysfunction. In both
the primary intention-to-treat analysis and the subsequent
analyses adjusting for crossovers, patients undergoing2462 The Journal of Thoracic and Cardiovascular SurCABG did face an early higher risk related to perioperative
mortality, and this higher up-front risk of surgery
needs to be an inherent part of the discussions with
patients, balanced against the longer-term benefits of
revascularization.
Subgroup Analyses of CABG Versus Medical
Therapy
Several ancillary analyses of the STICH trial have been
reported that explore potential subgroups of patients with
LV dysfunction who may be most likely to benefit from
CABG. The presence and extent of myocardial viability
was addressed in a prospectively designed STICH
substudy,29 with 601 of the 1212 patients imaged
with single-photon emission tomography or low-dose
dobutamine echocardiography to determine the magnitude
of viable myocardium. Using prespecified definitions of
extent of myocardial viability, patients with predominately
viable myocardium had reduced mortality compared
with those with predominately nonviable myocardium:
37% versus 51%, respectively, over a median 5.1-year
follow-up period. However, no significant interactions
were found among presence or absence of viable
myocardium, assignment to CABG or medical therapy,
and survival. Additional prespecified secondary analyses
that were based on median viability scores or on a
continuous model of viability and risk similarly revealed
no significant interactions.
These findings run counter to the prevailing opinions
that myocardial viability testing would identify those
patients most likely to benefit from CABG, based on
numerous previous imaging studies assessing survival
with CABG compared with medical therapy, and most
notably, a meta-analysis of viability studies by Allman
and colleagues.30 The major weakness of these previous
studies, in addition to their retrospective design and
heterogeneous definitions of myocardial viability, is that
the medical management would be considered inadequate
by today’s standards. For example, the many reports
summarized by Allman and colleagues30 were performed
in the 1980s and 1990s, and very few (if any) patients
received beta-blockers, reflected in the 16% annual
mortality rate reported in patients with viable myocardium
treated medically. In contrast, the annual mortality rate
with medical therapy in patients with viable myocardium
in the STICH trial was only 7.1%, despite the greater
degree of LV dysfunction (mean EF of 26.7% in the
STICH trial compared with 32.9% in the meta-analysis).
Although the STICH trial viability data cannot be
considered conclusive, they are supported by data in a
smaller randomized trial of CABG versus medical therapy
in patients with ischemic LV dysfunction and evidence of
myocardial viability, in which CABG did not result in
improved survival.31gery c December 2014
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revascularization12 continue to recommend that CABG
surgery in patients with LV dysfunction be considered in
the presence of viable myocardium, but cite only the
meta-analysis by Allman and colleagues30 in support of
this recommendation. As noted, none of the studies
summarized in that meta-analysis provided current,
aggressive, evidence-based therapies (particularly beta-
blockers) in the patients receiving ‘‘medical management.’’
The European guidelines for management of heart failure32
do not recommend CABG (class III) surgery in patients
with LV dysfunction without angina and without
myocardial viability. In contrast, the 2013 U.S. guidelines
for management of heart failure33 indicate that it is
reasonable to consider CABG in patients with moderate
LV dysfunction (EF, 35%-50%) and multivessel CAD or
disease of the proximal left anterior descending artery
when viable myocardium is present. However, in patients
with severe LV dysfunction (EF,<35%), CABG may be
considered with the intent of improving survival, whether
or not viable myocardium is present. These latter
recommendations are in keeping with the results of the
STICH trial.
Additional analyses of the STICH trial demonstrated that
the differences in the effect of CABG on survival is not
influenced by the presence and extent of inducible
myocardial ischemia34 or by circulating levels of
biomarkers35 such as brain natriuretic peptide and soluble
tumor necrosis factor-a receptor-1. Rather, improved
survival with CABG seems to be predicated on preserved
functional status, as assessed by the Kansas City
Cardiomyopathy Questionnaire or the 6-minute walk
test,36 and markers of angiographic severity of CAD,
severity of LV systolic dysfunction, and extent of LV
remodeling.37 Thus, survival after CABG is related to
functional status of the patient, severity of CAD, and
severity of LV remodeling, and less to objective markers
of viability or ischemia. Patients most likely to benefit are
those with the most-severe CAD and most-advanced LV
dysfunction. These are also the patients at greatest risk.
Surgical Ventricular Reconstruction
Whether it is advisable to add SVR to a CABG
procedure, with the intent to restore LV size and shape,
and in so doing enhancing LV reverse remodeling beyond
what can be achieved with revascularization and aggressive
medical management, has been the subject of considerable
discussion and controversy. Although this procedure had
strong proponents and encouraging clinical results,38,39
previous studies were observational and unblinded in
nature, and SVR had never been subjected to a
prospective clinical trial comparing the results with those
of CABG alone, particularly against the background of
intensive evidence-based medical therapy. The SVRThe Journal of Thoracic and Carhypothesis of the STICH trial40 addresses this gap, enrolling
1000 patients with LV dysfunction, CAD amenable to
CABG, and anterior wall akinesia or dyskinesia amenable
to SVR. Of these, 499 were randomized to receive CABG
alone, and 501 to receive CABG plus SVR.
As anticipated, SVR resulted in significantly smaller LV
volumes, but no difference was found in the primary
combined endpoint of all-cause mortality and cardiac
hospitalization, during the median follow-up of 4 years,
between patients receiving CABG or CABG plus SVR,
which occurred in 59% and 58% of patients, respectively.
In addition, no differences were found in the rate of individ-
ual secondary endpoints including all-cause mortality, hos-
pitalization, myocardial infarction, and stroke. Quality
measures also did not differ between the 2 groups, although
SVR resulted in greater utilization of health care re-
sources.41 Patients more likely to benefit from SVR proce-
dures are those with smaller, less-remodeled left
ventricles,42 whereas the extent of myocardial viability in
the anterior wall does not seem to be an important determi-
nant of outcomes of SVR compared with CABG alone.43CONCLUSIONS
With the increasing global burden of heart failure, it is
important to recognize that CAD is the leading cause of
LV systolic dysfunction in developed countries of theworld,
and in many developing countries as well. CAD as the
causative etiology results in a more aggressive
natural history, with higher mortality rates than
nonischemic etiologies,44 particularly in patients with the
most-severe degrees of LV dysfunction45 (EF <35%).
Although evidence-based medical therapy remains the
foundation for treatment of all patients with LV systolic
dysfunction, CABG provides the potential for incremental
survival benefit, particularly among the highest-risk
patients with multivessel disease and the most severely
remodeled ventricles. The results of the prospective STICH
trial26 support those of many earlier nonrandomized
studies,13-17 showing that the longer-term survival benefit
in patients who undergo CABG compared with medical
therapy alone tends to offset the short-term perioperative
mortality risk. Decisions to proceed with CABG in the
highest-risk patients need to be made judiciously and are
best deliberated with coordinated input from a dedicated
multidisciplinary heart team.References
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